Earning Position: How Evidence Becomes Authority
Diagnostics fail not analytically but through Evidence Escape: evidence does not automatically become clinical authority. Seven evidence domains govern adoption—analytical, clinical, regulatory, economic, operational. Strength in one domain cannot compensate for weakness elsewhere. The binding-constraint principle identifies the missing domain preventing adoption. Connected laboratories are evidence-generating assets, not merely deployment sites. Authority emerges only when evidence is designed as an integrated system, not isolated tasks.
Published April 2026
Miguel Oliveira
IVD Industry Monograph No. 2 — Persodia Research
Why does this matter now?
A diagnostic technology can demonstrate biological validity, analytical performance and clinical relevance. It can meet regulatory requirements and be available at scale.
It may still fail to reach sustained clinical use.
This is not an anomaly. It is a recurring structural condition across diagnostics markets.
Evidence accumulates, but it does not necessarily arrive in practice in the form required for action. As the industry faces growing demands for clinical proof, health-economic justification and operational integration, understanding how evidence becomes authority is increasingly important.
The central problem
A diagnostic test can be proven to work by every standard medicine recognises and still remain underused for decades.
The gap between what evidence warrants and what practice delivers is not necessarily a failure of science or execution. It is a structural condition.
Evidence does not become authority through accumulation alone. It becomes authority when it is recognised, accepted and acted upon across the system in which it operates: by actors the manufacturer does not control, on timelines it does not set and under criteria it did not define.
This is Evidence Escape.
It governs every diagnostic technology attempting to move from regulatory clearance to sustained clinical use.
What this monograph examines
Authority in diagnostics is not granted once.
It forms across multiple domains: analytical, clinical, regulatory, economic and operational. Each is governed by different actors and evaluated under different conditions.
Strength in one domain does not compensate automatically for absence in another.
The monograph examines:
- the structural condition separating evidence from authority;
- the seven evidence domains governing adoption;
- the binding-constraint principle: weakness in one domain may limit the value of strength elsewhere;
- field observations from ESCMID Global Munich 2026 across six companies and the wider clinical-scientific programme;
- the connected laboratory as an under-recognised evidence-generating asset;
- the alignment logic determining whether evidence becomes position or remains valid but unused.
The connected laboratory asset
A connected laboratory is not simply a deployment site.
It is also an evidence-generating environment.
Operational data, workflow experience and clinical context can contribute materially to the evidence architecture surrounding a diagnostic technology. Yet the industry has not always recognised the full strategic value of those assets.
The question is no longer only whether a product works. It is whether the system surrounding the product is capable of generating, interpreting and translating the evidence required for sustained position.
Analytical basis
The monograph draws on the structural framework developed in Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence and on direct field observation at ESCMID Global Munich 2026.
It is the second publication in the IVD Industry Monograph series: the primary analytical output of Persodia Research.
Strategic implications
Diagnostic companies should not treat evidence generation as a sequence of isolated clinical, regulatory or reimbursement tasks. The evidence system must be designed as a whole.
Executives should identify the binding evidence constraint early: the absent or insufficient domain most likely to prevent adoption even when other evidence is strong.
Investors should distinguish between technologies with impressive analytical validation and technologies with a credible path towards authority across the full adoption system.
Laboratories should consider their role not simply as deployment sites but as connected evidence assets.
Evidence that remains valid but unused does not create durable position.
Related Persodia material
Book
Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence
health.tech global summit 2026
About the series
Each monograph in the IVD Industry Monograph series examines a single structural question at the intersection of industry organisation, clinical deployment and market economics.
The series is observational rather than prescriptive, cumulative rather than episodic.
Assumed knowledge
The monograph assumes familiarity with the diagnostics industry and with the institutional conditions of clinical deployment.
Readers without direct commercial or technical experience in the sector will find the structural argument accessible but will benefit from prior reading of Inside the Clinical Diagnostics Industry.
Access
This monograph is available without charge.
Access requires a brief declaration of context and intended use. Persodia Research wishes to understand who engages with the material and in what professional context.
Full copyright is retained by the author. The material may be read, cited and discussed freely. It may not be reproduced or repurposed without prior written permission.
Request Automatic Download
IVD Industry Monograph No. 1
Enter your details below. A secure, single-use link will be sent to your email address. The link can be used once and does not expire.